Solving the Problem of Insolubility: Part II
KinetiSol’s solvent-free mixing process turns “brick dust” drugs into stable amorphous dispersions
False
KinetiSol’s solvent-free mixing process turns “brick dust” drugs into stable amorphous dispersions
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
False
False
November 19, 2026
5 min read
AI could soon allow scientists to model a drug’s journey from molecular structure through manufacturing to how it behaves in patient
November 17, 2026
5 min read
Estelle Verger and Nicolas Voisin from Aptar Pharma’s Injectables business discuss component quality, the changing needs of injectable therapies, and what to expect from a component partner.
November 17, 2026
6 min read
Regeneron’s Andres Sirulnik reflects on the experiences that took him from treating leukemia patients to developing medicines – and why following the science still means putting patients first
November 16, 2026
1 min read
CAR T pioneer John Maher reflects on the value of curiosity, career-defining setbacks, and pursuing unpopular ideas
False
Affiliations:
Specialties:
Areas of Expertise: